Navigation Links
Team Develops Anti-Infection Technology
Date:7/10/2009

MORGANTOWN, W.Va., July 10 /PRNewswire-USNewswire/ -- Combat-related injuries have long plagued the military in part because of multidrug-resistant bacteria. Imagine being able to spray a compound fracture with microcapsules that deliver a drug to bolster the immune system, stopping infection before it starts.

That technology might be around the corner, says Bingyun Li, Ph.D., of the West Virginia University Department of Orthopaedics and director of the WVU Biomaterials, Bioengineering & Nanotechnology Laboratory. Li's team has developed a drug-delivery technology involving microcapsules - and a second technique, nanocoating - that have been shown to work in animal studies.

Results of the team's research involving the drug interleukin-12, a drug currently in anti-cancer clinical trials, has been published in the May issue of the journal Biomaterials. A deeper explanation of the approach, which could develop into an alternative to antibiotic therapy, is scheduled to be published in an upcoming issue of the Journal of Orthopaedic Research.

"These pioneering techniques could be important to the United States because of the wars in Iraq and Afghanistan," Li says. "The treatment of battlefield casualties is expensive, and the infection rate runs from 2 percent to 15 percent. In some cases, because the organisms have developed resistance, antibiotics don't work."

Outside the arena of warfare, millions of people could potentially be helped by the technology because infections can result whenever a biomedical device is implanted.

Li's team developed two ways to deliver interleukin-12.

The first is in microcapsules that can be injected or, potentially, delivered in a fine-mist spray directly to the site of an injury. The second is a nanocoating of interleukin-12 applied directly to stents, pacemakers, pain pumps, artificial limbs - virtually any biomedical device - before implantation. The coating is measured on the nano scale; one nanometer is one billionth of a meter.

"Interleukin-12 will maximize the body's natural response to an extent where infections can be prevented without the risk of the offending bacteria developing resistance to the treatment, as is becoming more of a problem with antibiotic therapy alone. With nanocoating, the drug is right where it needs to be - at the interface of the implant and your tissue," Li said. "With the microcapsule, the drug can be injected or sprayed where desired, and the nanocoating and microcapsule prolong the half-life of interleukin-12."

In both methods, because the interleukin-12 is delivered locally rather than spread throughout the body, as in antibiotic therapy, side effects are minimal, Li explained.

Li drew his team from the WVU Department of Orthopaedics, the WVU School of Pharmacy, the National Institute for Occupational Health and Safety (NIOSH), and the WVU Department of Microbiology, Immunology and Cell Biology.

Li, who is also a guest researcher with NIOSH, is giving a presentation on the technology later this summer to officials from the Naval Medical Research Center in Silver Spring, Maryland. He is also working with Christopher Kolanko, Ph.D., a Department of Defense consultant for the WVU Research Corporation, and program managers with the Department of Defense, to discuss further research possibilities and possible military applications.

Li's team has spent the past four years developing the technology, funded in part by the WVU Research Corporation, the National Science Foundation and the Osteosynthesis and Trauma Care Foundation.

This news release was issued on behalf of Newswise(TM). For more information, visit http://www.newswise.com.


'/>"/>
SOURCE West Virginia University Health Sciences Center
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Couples more likely to divorce if spouse develops cervical or testicular cancer
2. Corey McPherson Nash Develops Case Statement for Dana-Farber Cancer Institute Capital Campaign
3. UCLA doctor develops new technique to treat varicose veins
4. Biomarkers predict risk for invasive breast cancer years before the tumor develops
5. Silverchair Learning Systems Updates and Develops New Courses
6. OHSU Cancer Institute researcher develops test for targeted therapy in acute myeloid leukemia
7. Capsulated Systems, Inc. Develops Long Term Local Anesthetic
8. MIT develops thin-film micro pharmacy
9. Omron Healthcare Develops Solar-Powered Digital Blood Pressure Monitors
10. Psychologist develops post-operative care for heart patients in Bermuda
11. Medical Records Institute (MRI) Develops Initiative for EMRs Supporting Medicolegal Requirements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the ... AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in ... topics including advance care planning, healthcare costs and patient and family engagement. , ...
(Date:6/25/2016)... FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial ... Plant City Observer , brings up a new, often overlooked aspect of head lice: the ... closing for fumigation is not a common occurrence, but a necessary one in the event ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the largest ... as the Medical Director of its new Mesquite-Samuell Farm facility. , “We are ... Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, ... the latter, setting the bar too high can result in disappointment, perhaps even self-loathing. ... toward their goal. , Research from PsychTests.com reveals that behind the ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...   Bay Area Lyme Foundation , collaborating ... for Tick Borne Illness , Harvard Medical School ... Medicine, University of California, Berkeley, and the Veterans ... finalists of Lyme Innovation , the first ... scientists, clinicians, researchers, entrepreneurs, and investors from several ...
(Date:6/24/2016)... Va. , June 24, 2016 The ... set of recommendations that would allow biopharmaceutical ... (HCEI) with entities that make formulary and coverage decisions, ... the "value" of new medicines. The recommendations ... does not appear on the drug label, a prohibition ...
(Date:6/24/2016)... -- Research and Markets has announced the addition ... report to their offering. ... The World Market for Companion Diagnostics covers the world ... in the report includes the following: , ... by Region (N. America, EU, ROW), 2015-2020 , World ...
Breaking Medicine Technology: